Massive parallel sequencing

PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study

Retrieved on: 
Martedì, Maggio 28, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, NGS, Partnership, Patient, Novartis, Data, Massive parallel sequencing, Johnson & Johnson, Clinical trial, PCC, EGFR, GSK, AI, Cancer, ASCO, Lung cancer, LLM, Roche, Artificial intelligence, AstraZeneca, Eli Lilly and Company, Multimedia, Roger Hawkins (drummer), Medical imaging

This study rigorously tested Massive Bio's existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform.

Key Points: 
  • This study rigorously tested Massive Bio's existing artificial intelligence (AI) system, designed to refine the clinical trial matching process using real-world clinical and genomic data, focused on a multi-study oncology platform.
  • View the full release here: https://www.businesswire.com/news/home/20240528545627/en/
    PCC and Massive Bio Validate Existing AI System in Groundbreaking and Largest Multi-Sponsor Clinical Trial Matching Study (Graphic: Business Wire)
    Manual screening of patients for cancer trials is traditionally a resource-intensive process, taking about 25 minutes per trial and limiting patient access to suitable trials.
  • In response, Massive Bio and the PCC implemented an advanced multi-trial matching method that integrates Next-Generation Sequencing (NGS) results and utilizes AI to enhance both the accuracy and efficiency of trial matching, particularly for targeted therapies.
  • Trial Matching Improvements: The study matched 690 unique patients to at least one trial, creating 1,254 patient-trial pairs—a 1.82-fold increase due to the multi-trial matching approach.

Global gRNA Market to Surpass USD 1.62 Billion by 2030 with Robust Growth in Next-Generation Sequencing and Genome Engineering Applications - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Marzo 14, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Growth, Gene editing, NGS, Research, RNA, Lead, Massive parallel sequencing, Guide, Good laboratory practice, IND, Medicine, Inde, Investment, CRISPR, USD, GLP, Pharmaceutical industry

The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.

Key Points: 
  • The global gRNA (guide RNA) market is witnessing an unprecedented surge, with projections estimating its growth to reach USD 1.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 18.6% from 2024 to 2030.
  • The latest market report on the global gRNA industry, now available for review, emphasizes the utility of products and custom gRNA synthesis services, and the ever-expanding realm of research applications.
  • Pharmaceutical and biotechnology companies are leveraging gRNA to pioneer advancements in precision medicine, positioning themselves as key end-users and market growth propellants.
  • The integration of advanced technologies and the discovery of novel applications are key to sustaining this growth momentum.

Europe Cancer Diagnostics Market Sees Promising Growth Amid Rising Demand for Precision Diagnostics - Forecasts to 2031

Retrieved on: 
Venerdì, Marzo 1, 2024
MRI, Incidence, Breast cancer, Sequencing, Comprehensive, Traction, Hospital, Strategic planning, Growth, Implementation, Massive parallel sequencing, NGS, Lung, Patient, Optimism, Diagnosis, PCR, IVD, Cancer, Medical imaging

The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.

Key Points: 
  • The latest report on the Europe cancer diagnostics market projects a robust growth trajectory for the industry, setting high expectations for advancements in cancer care across the continent.
  • At what rate is the demand for cancer diagnostic products in Europe projected to grow for the next 5-7 years?
  • Which countries are expected to offer significant growth opportunities for the vendors operating in the Europe cancer diagnostics market?
  • What recent developments have taken place in the Europe cancer diagnostics market, and how these strategic developments are creating an impact in this market?

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Gennaio 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Sequentify Awarded Grant by Israel Innovation Authority for Infectious Disease Sequencing Panel

Retrieved on: 
Giovedì, Gennaio 11, 2024
DNA, Infection, Diagnosis, IIA, Research, Massive parallel sequencing, Pharmaceutical industry

REHOVOT, Israel, Jan. 11, 2024 /PRNewswire/ -- Sequentify, a company specializing in DNA sequencing technology, has been granted funding by the Israel Innovation Authority (IIA). This grant, contributing to a project totaling $1.3 million, supports the development of Sequentify's targeted sequencing panel for infectious disease research. The panel aims to provide a culture-free, next-day solution for sequencing pathogens, focusing on pathogen diagnosis and antibiotic resistance surveillance.

Key Points: 
  • Sequentify Secures Funding to Advance Culture-Free, Rapid Pathogen Sequencing Technology
    REHOVOT, Israel, Jan. 11, 2024 /PRNewswire/ -- Sequentify , a company specializing in DNA sequencing technology, has been granted funding by the Israel Innovation Authority (IIA).
  • This grant, contributing to a project totaling $1.3 million, supports the development of Sequentify's targeted sequencing panel for infectious disease research.
  • The panel aims to provide a culture-free, next-day solution for sequencing pathogens, focusing on pathogen diagnosis and antibiotic resistance surveillance.
  • Sequentify's development of this sequencing panel reflects its ongoing commitment to contributing valuable tools for infectious disease research and management.

CCM Biosciences Announces Launch of 5Prime Sciences Business Unit

Retrieved on: 
Mercoledì, Dicembre 27, 2023
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, RNA, Entrepreneurship, Polymerization, NGS, Princeton University, DNA, Doctor of Philosophy, PCR, DdPCR, CDX, Diagnosis, Spectrum, Big data, Gene, IVD, Bias, Machine learning, Enzyme, CCM, Q5, RNA-Seq, Massive parallel sequencing, Algorithm, Synthetic biology, History, Fragile X syndrome, Vaccine

Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (5Prime) focused on the development and application of proprietary technology in the domain of DNA biotechnology.

Key Points: 
  • Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (5Prime) focused on the development and application of proprietary technology in the domain of DNA biotechnology.
  • 5Prime’s technology platform includes multiple patent-protected, globally commercialized compositions and methods for molecular cloning, next-generation DNA sequencing and molecular diagnostics.
  • In the context of molecular diagnostics, NGS is typically applied to diagnose in high-throughput the patterns of DNA mutations in genes.
  • ddPCR is a sensitive method for diagnosing mutations in specific disease-associated genes that is also limited by problems of sequence bias.

PerkinElmer Acquires Covaris to Create an Innovation-Led, Global Life-Sciences and Diagnostics Platform

Retrieved on: 
Lunedì, Dicembre 4, 2023
Manufacturing, Other Health, Environment, Other Science, Pharmaceutical, Research, Other Technology, Sustainability, Medical Devices, Hardware, Science, Technology, Medical Supplies, General Health, Agriculture, Natural Resources, Health, Health Technology, Chemicals, Plastics, Massive parallel sequencing, Safety, DNA, Laboratory, Food, Genomics, Medicine, Data analysis, PerkinElmer, DNA fragmentation, Drug discovery, Growth, NGS, Fine chemical, Renewable energy, Eddy covariance

The merger will accelerate Covaris’ growth potential and expand PerkinElmer’s existing life sciences portfolio into the high-growth diagnostics end market.

Key Points: 
  • The merger will accelerate Covaris’ growth potential and expand PerkinElmer’s existing life sciences portfolio into the high-growth diagnostics end market.
  • Covaris’ solutions empower customers to accelerate the pace of research and drug discovery for clinical diagnostics, biopharma, and research markets globally.
  • We see significant growth opportunities resulting from the combined resources of both companies, with PerkinElmer’s global scale unlocking commercial opportunities for Covaris,” said Dirk Bontridder, CEO of PerkinElmer.
  • Covaris will now have access to PerkinElmer’s global reach, technical and operating capabilities to continue its rapid growth trajectory.

Leal Health Presents Poster Highlighting Strong Correlation Between Education, Engagement and Access to Clinical Trials with Improved Outcomes of Breast Cancer Patients

Retrieved on: 
Lunedì, Dicembre 11, 2023
Massive parallel sequencing, Organization, Breast cancer, Disease, Clinical trial, Patient, Genetic testing, Leal, Survival, CDC, Doctor of Philosophy, NGS, Biomarker, Knowledge, Poster, Health, Education, Medical imaging, Pharmaceutical industry

NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that the Company presented a poster at the 2023 San Antonio Breast Cancer Symposium (SABCS), held on December 5th-9th, highlighting the critical relationship between education, engagement and access to cancer clinical trials, and improved outcomes of breast cancer patients.

Key Points: 
  • The presentation showcased data from a diverse cohort of 14,509 breast cancer patients, emphasizing the critical relationship between care access factors and overall survival.
  • Notably, the study utilized real-world CDC data to correlate survival, with multiple factors relevant for the identification and enrollment in oncology clinical trials.
  • Tzvia Bader, CEO of Leal Health, added, "It's evident that education and access are crucial for better patient care.
  • Looking ahead, our goal remains clear: to bridge knowledge gaps, remove access hurdles and democratize cancer care for all patients."

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Giovedì, Dicembre 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.

Per-Encounter Medical Market to Hit $327.84 Billion, Globally, by 2030 at 16% CAGR: Coherent Market Insights

Retrieved on: 
Giovedì, Dicembre 7, 2023
DNA, Conditional sentence, Patient, Segment, Prostate, Therapy, Diagnosis, Growth, Neurology, Hospital, Stroke, DNA synthesis, ChromeOS, Telehealth, Massive parallel sequencing, Ambulatory Surgery Center Association, Food, Prevalence, Cardinal Health, Catheter, Catalent, Suture, Drug development, NGS, Synthetic biology, SPECT, Syringe, Market, Bandage, Cardiology, Research, Biotechnology, Health information management, FDG, PET, Stent, Classification, EHR, De novo, Distribution, Countertop, Cardiovascular disease, TURP, Medication, COVID-19, Death, Splenic infarction, Oncology, Beauty salon, Health insurance, Medical imaging, Pharmaceutical industry, Medical device, Geography, Endocrinology, Application, Vygon (UK)

The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.

Key Points: 
  • The Per-Encounter Medical Market is influenced by various factors that drive its growth and reshape its landscape.
  • Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/6386
    Another driver boosting the growth of the Per-Encounter Medical Market is the demand for personalized healthcare services.
  • Per-encounter medical services enable healthcare providers to deliver personalized care by facilitating a one-on-one relationship between the patient and the healthcare professional.
  • Read complete market research report," Per-Encounter Medical Market, By Product Type, By Application, By Distribution Channel, By Region, and Segment Forecast 2023-2030 ", Published by Coherent Market Insights.